Analysis of Use of New Anti-Tumor Drugs in the First Affiliated Hospital of University of Science and Technology of China from 2017 to 2020

CHENG Xi; SHEN Aizong

doi:10.14009/j.issn.1672-2124.2021.09.021

您当前的位置：

首页 >

文章列表页 >

Analysis of Use of New Anti-Tumor Drugs in the First Affiliated Hospital of University of Science and Technology of China from 2017 to 2020

更新时间：2022-10-08

- Analysis of Use of New Anti-Tumor Drugs in the First Affiliated Hospital of University of Science and Technology of China from 2017 to 2020
- Vol. 21, Issue 9, Pages: 1109-1113(2021)
- 作者机构：
  
  中国科学技术大学附属第一医院/安徽省立医院药剂科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2021.09.021
  CLC： R979.1
- Published：2021，
扫描看全文
CHENG Xi, SHEN Aizong. Analysis of Use of New Anti-Tumor Drugs in the First Affiliated Hospital of University of Science and Technology of China from 2017 to 2020. [J]. 21(9):1109-1113(2021)
DOI：

CHENG Xi, SHEN Aizong. Analysis of Use of New Anti-Tumor Drugs in the First Affiliated Hospital of University of Science and Technology of China from 2017 to 2020. [J]. 21(9):1109-1113(2021) DOI： 10.14009/j.issn.1672-2124.2021.09.021.

摘要

目的:了解中国科学技术大学附属第一医院(以下简称"我院")新型抗肿瘤药的临床使用情况

为合理用药提供参考。方法:采用回顾性的方法

对2017—2020年我院新型抗肿瘤药的销售金额、用药频度(defined daily dose system

DDDs)、限定日费用(defined daily cost

DDC)及药品销售金额排序(B)/DDDs排序(A)进行统计分析。结果:2017—2020年

我院新型抗肿瘤药的销售金额呈现出波动的态势

从2017年的7 696.00万元减少至2018年的6 536.05万元

减少了15.07%; 2019年增长至8 588.94万元

较2018年增长了31.41%; 2020年又减少至4 426.18万元

较2019年减少了48.47%。然而

新型抗肿瘤药的品种数则逐年递增

从2017年的21个增长至2020年的53个。2017—2020年

伊马替尼的销售金额排序、DDDs排序均居第1位;2017—2019年

尼洛替尼、利妥昔单抗和硼替佐米的销售金额排序均居前5位; 2017—2020年

吉非替尼、达沙替尼及埃克替尼的B/A>1

提示其价格低

使用频率高;大部分药品的DDC相对稳定

B/A接近于1

提示其销售金额与DDDs的同步性总体较好。结论:我院新型抗肿瘤药的临床使用相对合理

药品价格、上市时间及临床适应证对该类药品的使用影响较大。

Abstract

OBJECTIVE: To probe into the clinical use of new anti-tumor drugs in the First Affiliated Hospital of University of Science and Technology of China（ hereinafter referred to as “our hospital”）

so as to provide reference for rational drug use. METHODS: Retrospective analysis was adopted

the consumption sum

defined daily dose system（ DDDs）

defined daily cost（ DDC） and consumption sum ranking（ B）/DDDs ranking（ A） of new anti-tumor drugs in our hospital from 2017 to 2020 were analyzed statistically. RESULTS: From 2017 to 2020

the consumption sum of new anti-tumor drugs in our hospital showed the trend of fluctuation

decreased from 76 960 000 yuan in 2017 to 65 360 500 yuan in 2018

with the decrease of 15. 07%. In 2019

the consumption sum increased to 85 889 400 yuan

with the increase of 31. 41% over 2018. In 2020

the consumption sum decreased to 44 261 800 yuan

with the decrease of 48. 47% over 2019. However

the number of new anti-tumor drugs increased year by year

from 21 in 2017 to 53 in 2020. From 2017 to 2020

imatinib took the lead in terms of consumption sum and DDDs. From 2017 to 2019

the consumption sum of nilotinib

rituximab and bortezomib ranked the top 5. From 2017 to 2020

the B/A of gefitinib

dasatinib and ectinib was higher than 1

suggesting lower price and higher frequency of use. The DDC of most drugs was relatively stable

with B/A close to 1

indicating that the consumption sum was in good synchronization with DDDs. CONCLUSIONS: The clinical use of new anti-tumor drugs in our hospital is relatively reasonable

and drug price

marketing time and clinical indications have greater influence on the use of these drugs.

关键词

新型抗肿瘤药销售金额用药频度用药分析

Keywords

New anti-tumor drugsConsumption sumDefined daily dose systemApplication analysis

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Investigation and Analysis of Application of Tamoxifen and Toremifene in the Treatment of Breast Cancer in 15 Grade Ⅲ,Level A Hospitals in Shanghai from 2015 to 2019

Analysis of Application of Hospital Preparations in Sichuan Provincial People’s Hospital from 2017 to 2019

Analysis on the Application of Oral Lipid-Regulating Drugs in Chinese PLA General Hospital During 2016-2018

Analysis of Application of Glaucoma Treatment Drugs in 114 Grade Ⅲ Level A hospitals in China from 2015 to 2017

Intervention Effects of Special Management on Defined Daily Dose System and Rationality Evaluation Index of Carbapenem Antibiotics

Related Author

ZHAI Qing

YU Bo

DU Qiong

FAN Jiazuan

WANG Mengmeng

SHUAI Xiaocui

LI Huo

LI Jinqi

Related Institution

Dept.of Pharmacy,Fudan University Shanghai Cancer Center

Dept.of Oncology,Shanghai Medical College, Fudan University

Dept.of Pharmacy, Tongren Hospital,Shanghai Jiao Tong University School of Medicine

Dept. of Pharmacy,Sichuan Academy of Medical Sciences·Sichuan Provincial People’s Hospital,Personalized Drug Therapy Key Laboratory of Sichuan Province

Outpatient Pharmacy of Pharmacy Department,Medical Security Center,Chinese PLA General Hospital

⁰